Allogene Therapeutics: Q2 Earnings Snapshot

August 9, 2022 GMT

SOUTH SAN FRANCISCO, Calif. (AP) _ Allogene Therapeutics Inc. (ALLO) on Tuesday reported a loss of $74.8 million in its second quarter.

The South San Francisco, California-based company said it had a loss of 52 cents per share.

The results exceeded Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of 61 cents per share.

The immuno-oncology company posted revenue of $86,000 in the period.

Allogene Therapeutics shares have increased almost 1% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $15.03, a fall of 34% in the last 12 months.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on ALLO at